Shanghai Fosun Pharmaceutical
VerifiedShanghai Fosun Pharmaceutical a leading healthcare company in China
Launch date
Employees
Ownership
Market cap
CNY105.0b
Net debt
CNY34.2b
Firm valuation
$16.9b (Public information from Aug 2022)
Share price
CNY43.37
Shanghai Shanghai (HQ)
Deals in current and previous year:
Financials
Edit| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | - | 2.3b | 3.1b | 3.6b | 3.8b | 4.6b | 5.3b |
| % growth | - | - | 33 % | 16 % | 6 % | 21 % | 15 % |
| EBITDA | - | 628m | 430m | 734m | 785m | 675m | 838m |
| % EBITDA margin | - | 27 % | 14 % | 21 % | 21 % | 15 % | 16 % |
| Profit | - | 391m | 339m | 415m | 458m | 556m | 701m |
| % profit margin | - | 17 % | 11 % | 12 % | 12 % | 12 % | 13 % |
| EV / revenue | - | 6.6x | 2.9x | 2.7x | 4.6x | 3.0x | 2.6x |
| EV / EBITDA | - | 24.4x | 21.1x | 13.1x | 22.2x | 26.5x | 19.1x |
| R&D budget | 98m | 131m | 177m | 423m | - | - | - |
| R&D % of revenue | - | 6 % | 6 % | 12 % | - | - | - |
Source: Company fillings or news article
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Recent News about Shanghai Fosun Pharmaceutical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
Investments by Shanghai Fosun Pharmaceutical
Edit
exited
ACQUISITION by Shanghai Fosun Pharmaceutical Mar 2017
ACQUISITION by Alphatec Spine Dec 2020
ACQUISITION by Shanghai Fosun Pharmaceutical Oct 2017
